TR200200211T2 - Tedavi ve ilaç tarama yöntemleri. - Google Patents

Tedavi ve ilaç tarama yöntemleri.

Info

Publication number
TR200200211T2
TR200200211T2 TR2002/00211T TR200200211T TR200200211T2 TR 200200211 T2 TR200200211 T2 TR 200200211T2 TR 2002/00211 T TR2002/00211 T TR 2002/00211T TR 200200211 T TR200200211 T TR 200200211T TR 200200211 T2 TR200200211 T2 TR 200200211T2
Authority
TR
Turkey
Prior art keywords
treatment
screening methods
drug screening
prevent
cells
Prior art date
Application number
TR2002/00211T
Other languages
English (en)
Inventor
Neil Alexander Palmer Colin
Vosper Helen
Roland Wolf Charles
Original Assignee
The University Of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Dundee filed Critical The University Of Dundee
Publication of TR200200211T2 publication Critical patent/TR200200211T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/5055—Cells of the immune system involving macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

Makrofajlardan veya diger hücrelerden köpük hücre olusumunu önlemek veya azaltmak, veya köpük hücreleri gidermek için, veya kan damarlarinda plak formasyonu ve/veya pihti ile blokaji ile ilgili bir vasküler hastaligin önlenmesi veya tedavisi için; hastaya etkili bir miktarda bir PPAR delta aktivite inhibitörü verilmesini içeren bir yöntem.
TR2002/00211T 1999-07-23 2000-07-19 Tedavi ve ilaç tarama yöntemleri. TR200200211T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9917405.4A GB9917405D0 (en) 1999-07-23 1999-07-23 Methods of treatment and drug screening methods

Publications (1)

Publication Number Publication Date
TR200200211T2 true TR200200211T2 (tr) 2002-06-21

Family

ID=10857874

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2005/01763T TR200501763T1 (tr) 1999-07-23 2000-07-19 T
TR2002/00211T TR200200211T2 (tr) 1999-07-23 2000-07-19 Tedavi ve ilaç tarama yöntemleri.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TR2005/01763T TR200501763T1 (tr) 1999-07-23 2000-07-19 T

Country Status (29)

Country Link
EP (1) EP1200114B1 (tr)
JP (1) JP2003505058A (tr)
KR (1) KR20020012323A (tr)
CN (1) CN1364087A (tr)
AR (1) AR027832A1 (tr)
AT (1) ATE430577T1 (tr)
AU (1) AU6825900A (tr)
BR (1) BR0012661A (tr)
CA (1) CA2378462A1 (tr)
CO (1) CO5280202A1 (tr)
CY (1) CY1109255T1 (tr)
CZ (1) CZ2002247A3 (tr)
DE (1) DE60042161D1 (tr)
DK (1) DK1200114T3 (tr)
ES (1) ES2326785T3 (tr)
GB (1) GB9917405D0 (tr)
HK (1) HK1046094B (tr)
HU (1) HUP0201966A3 (tr)
IL (1) IL147363A0 (tr)
MX (1) MXPA02000880A (tr)
MY (1) MY140626A (tr)
NO (1) NO20020326L (tr)
NZ (1) NZ573856A (tr)
PL (1) PL205747B1 (tr)
PT (1) PT1200114E (tr)
SI (1) SI1200114T1 (tr)
TR (2) TR200501763T1 (tr)
WO (1) WO2001007066A2 (tr)
ZA (1) ZA200200542B (tr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001277926B2 (en) * 2000-07-20 2006-02-16 Bristol-Myers Squibb Company Regulators of PPARdelta(beta) and their use in the treatment of obesity and insulin resistance
EP1357914A2 (en) * 2001-02-02 2003-11-05 SmithKline Beecham Corporation Treatment of ppar mediated diseases
GB0103809D0 (en) 2001-02-16 2001-04-04 Univ Dundee Methods
AU2003220521A1 (en) * 2002-03-27 2003-10-13 Smithkline Beecham Corporation Methods of treatment with lxr modulators
GB0302446D0 (en) * 2003-02-03 2003-03-05 Imp College Innovations Ltd Screening for modulators of fat storage
EP1637161A4 (en) * 2003-04-22 2007-06-27 Astellas Pharma Inc MEANS FOR THE TREATMENT OF NEURODEGENERATIVE ILLNESSES OF THE BRAIN WITH PPAR [delta] AGONIST
WO2006037031A2 (en) * 2004-09-27 2006-04-06 Valentis, Inc. Formulations and methods for treatment of inflammatory diseases
DE102006033394A1 (de) * 2006-07-13 2008-01-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zum Auffinden von antiatherosklerotischen Substanzen
BRPI0807023A2 (pt) * 2007-01-08 2014-04-22 Seoul Nat Univ Ind Foundation Composto de tiazol como ligante de ppard e produto farmacêutico, cosmético e alimento saudável dele composto
CN112168820B (zh) * 2019-07-05 2023-09-29 中国科学院生物物理研究所 SRCAP ATPase抑制剂在结直肠癌治疗中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157025A (en) * 1991-04-01 1992-10-20 E. R. Squibb & Sons, Inc. Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
AU1856997A (en) * 1996-02-02 1997-08-22 Merck & Co., Inc. Method for raising hdl cholesterol levels
KR100343832B1 (ko) * 1996-08-27 2002-07-20 시오노기세이야쿠가부시키가이샤 크로멘-3-카르복실산 유도체
DE69726182T2 (de) * 1996-12-11 2004-08-12 Dana-Farber Cancer Institute, Inc., Boston Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
WO1998043081A1 (en) * 1997-03-26 1998-10-01 Ligand Pharmaceuticals Incorporated Treatment of gastrointestinal disease with ppar modulators
WO1999000491A1 (en) * 1997-06-27 1999-01-07 Ono Pharmaceutical Co., Ltd. Novel plasmid dna containing reporter gene dna and use of the same
AU8355998A (en) * 1997-07-24 1999-02-16 Yamanouchi Pharmaceutical Co., Ltd. Medicinal compositions with cholesterol-lowering effect
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases

Also Published As

Publication number Publication date
AR027832A1 (es) 2003-04-16
PT1200114E (pt) 2009-07-09
HK1046094A1 (en) 2002-12-27
CN1364087A (zh) 2002-08-14
DE60042161D1 (de) 2009-06-18
CZ2002247A3 (cs) 2002-11-13
TR200501763T1 (tr) 2009-03-23
IL147363A0 (en) 2002-08-14
EP1200114B1 (en) 2009-05-06
GB9917405D0 (en) 1999-09-22
WO2001007066A2 (en) 2001-02-01
CO5280202A1 (es) 2003-05-30
NO20020326L (no) 2002-03-20
JP2003505058A (ja) 2003-02-12
CY1109255T1 (el) 2014-07-02
EP1200114A2 (en) 2002-05-02
PL205747B1 (pl) 2010-05-31
ZA200200542B (en) 2003-07-30
KR20020012323A (ko) 2002-02-15
PL364749A1 (en) 2004-12-13
ES2326785T3 (es) 2009-10-20
ATE430577T1 (de) 2009-05-15
AU6825900A (en) 2001-02-13
HK1046094B (en) 2009-10-02
MXPA02000880A (es) 2003-07-14
NO20020326D0 (no) 2002-01-22
NZ573856A (en) 2010-06-25
DK1200114T3 (da) 2009-08-03
HUP0201966A2 (en) 2002-09-28
BR0012661A (pt) 2002-04-09
CA2378462A1 (en) 2001-02-01
TR200501763T2 (tr) 2005-08-22
HUP0201966A3 (en) 2005-01-28
SI1200114T1 (sl) 2009-10-31
WO2001007066A3 (en) 2001-08-09
MY140626A (en) 2010-01-15

Similar Documents

Publication Publication Date Title
CY1109255T1 (el) Ppar δελτα αναστολεις για την αντιμετωπιση καρδιαγγειακων νοσων
DE60019618D1 (de) Greifvorrichtung für intravaskuläres filter
DE60107815D1 (de) Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
ATE355852T1 (de) Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten
SE9702860D0 (sv) New use
ATE292979T1 (de) Verwendung von aktiviertem protein-c zur behandlung überschiessender blutgerinnung bei sepsis
LU92615I2 (fr) Alogliptin et ses dérivés pharmaceutiquement acceptables (VIPIDIA)
WO2002015920A3 (en) Treatment of hyperproliferative diseases
WO2001024783A3 (de) Verwendung von (+)-tramadol, o-demethyltramadol bzw. (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol bzw. (+)-o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
WO2004037208A3 (en) Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
AU6539000A (en) Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
JP2003530841A5 (tr)
DE60021111D1 (de) Verwendung von fibrinolytischen metallproteinasen zur behandlung von blutgerinseln
DE50103012D1 (de) Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen
MXPA03000033A (es) Procedimiento de tratamiento de enfermedades vasculares perifericas, neuropatias perifericas y neuropatias autonomicas.
Neutel et al. P-373: A comparison of the effects of amlodipine 5 mg/benazepril 20 mg combination therapy to component monotherapy on arterial distensibilitly and left ventricular hypertrophy in patients with mild to moderate hypertension
Soulban The chronobiology of coagulation and the chronopharmacology of warfarin.
Schlanger et al. Reversible renal failure in an elderly woman with renal artery stenosis
Beckles et al. P-375: Attenuation of cardiac hypertrophy in vivo by interference with the jak/Stat pathway
魏启明 The Role of Chinese Medicine in Preventing Apoptosis and Oxidative Damage on Cardiomyocytes
WO2001008669A3 (en) Therapeutic agents for lymphoedema
McGill et al. Recent Publications of Interest
SE0102578L (sv) Förändring av en stents egenskaper för att förhindra restenos
ATE327736T1 (de) Liposomenhaltiges mittel zur behandlung gefässerkrankungen
Gwinner Photoperiodic synchronization of circannual rhythms